(MRK) Merck KGaA - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0006599905

LifeScienceTools, HealthcareDrugs, ElectronicsMaterials, TestingKits, Biopharmaceuticals

MRK EPS (Earnings per Share)

EPS (Earnings per Share) of MRK over the last years for every Quarter: "2020-03": 1.05, "2020-06": 0.67, "2020-09": 1.85, "2020-12": 1, "2021-03": 1.72, "2021-06": 1.71, "2021-09": 1.75, "2021-12": 1.84, "2022-03": 2.02, "2022-06": 1.99, "2022-09": 2.12, "2022-12": 1.51, "2023-03": 1.83, "2023-06": 1.62, "2023-09": 1.7, "2023-12": 1.35, "2024-03": 1.6, "2024-06": 1.4, "2024-09": 1.86, "2024-12": 1.53, "2025-03": 1.69,

MRK Revenue

Revenue of MRK over the last years for every Quarter: 2020-03: 4370, 2020-06: 4119, 2020-09: 4447, 2020-12: 4598, 2021-03: 4631, 2021-06: 4870, 2021-09: 4973, 2021-12: 5213, 2022-03: 5198, 2022-06: 5568, 2022-09: 5806, 2022-12: 5660, 2023-03: 5293, 2023-06: 5302, 2023-09: 5173, 2023-12: 5225, 2024-03: 5120, 2024-06: 5352, 2024-09: 5266, 2024-12: 5418, 2025-03: 5280,

Description: MRK Merck KGaA

Merck KGaA is a diversified science and technology company operating in three main segments: Life Science, Healthcare, and Electronics. The Life Science segment provides a range of products and services for research, development, and manufacturing in the pharmaceutical, biotech, and industrial sectors, including process development expertise, testing kits, and reagents. The Healthcare segment focuses on developing and marketing prescription drugs and biopharmaceuticals for various therapeutic areas, such as oncology, neurology, and immunology. The Electronics segment supplies materials and solutions for the semiconductor and display industries.

From a financial perspective, Merck KGaA has a market capitalization of approximately €47.5 billion, indicating a significant presence in the global pharmaceutical and technology industries. The companys price-to-earnings (P/E) ratio is around 17.43, suggesting a relatively reasonable valuation compared to its earnings. The forward P/E ratio is lower, at 12.56, indicating potential for future earnings growth. The return on equity (RoE) is around 9.67%, which is a respectable figure, although it may not be outstanding compared to some peers.

Some key performance indicators (KPIs) to consider when evaluating Merck KGaA include its revenue growth, operating margin, and research and development (R&D) expenditure as a percentage of sales. The companys R&D focus is evident from its multiple collaborations and licensing agreements, such as those with Debiopharm International SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., and Abbisko Therapeutics Co. Ltd. These partnerships aim to develop and commercialize new treatments for various diseases, including cancer and multiple sclerosis. A review of Merck KGaAs dividend yield and payout ratio could also provide insights into its ability to generate cash and return value to shareholders.

To further analyze Merck KGaAs prospects, it would be essential to examine its product pipeline, particularly in the Healthcare segment, where the company is developing new treatments for various therapeutic areas. The competitive landscape, including the positioning of its products and services relative to peers, is also crucial. Additionally, an assessment of the companys Electronics segment, including its supply chain and customer base, could provide insights into its growth potential and potential risks.

Additional Sources for MRK Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

MRK Stock Overview

Market Cap in USD 55,316m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception

MRK Stock Ratings

Growth Rating -20.8
Fundamental 33.0
Dividend Rating 40.0
Rel. Strength -18
Analysts -
Fair Price Momentum 98.43 EUR
Fair Price DCF 330.38 EUR

MRK Dividends

Dividend Yield 12m 1.76%
Yield on Cost 5y 2.03%
Annual Growth 5y -3.29%
Payout Consistency 90.0%
Payout Ratio 25.3%

MRK Growth Ratios

Growth Correlation 3m -81.2%
Growth Correlation 12m -95.5%
Growth Correlation 5y -8.2%
CAGR 5y 0.59%
CAGR/Max DD 5y 0.01
Sharpe Ratio 12m -0.52
Alpha -33.14
Beta 0.470
Volatility 27.26%
Current Volume 180.7k
Average Volume 20d 274.8k
Stop Loss 108.2 (-3%)
What is the price of MRK shares?
As of July 19, 2025, the stock is trading at EUR 111.55 with a total of 180,714 shares traded.
Over the past week, the price has changed by -2.53%, over one month by -0.49%, over three months by -2.60% and over the past year by -26.49%.
Is Merck KGaA a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, Merck KGaA is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.96 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRK is around 98.43 EUR . This means that MRK is currently overvalued and has a potential downside of -11.76%.
Is MRK a buy, sell or hold?
Merck KGaA has no consensus analysts rating.
What are the forecasts for MRK share price target?
According to our own proprietary Forecast Model, MRK Merck KGaA will be worth about 108 in July 2026. The stock is currently trading at 111.55. This means that the stock has a potential downside of -3.19%.
Issuer Target Up/Down from current
Wallstreet Target Price 159.9 43.3%
Analysts Target Price - -
ValueRay Target Price 108 -3.2%